Phase 2/3 Studies
SOUSEIKAI has been helping sponsors confirm the desired effects of their IP, doses of treatment for target populations' target indications, and to facilitate their overall global development process. After the initial complexities of Phase 1 studies are explored and understood, larger Phase 2 and Phase 3 studies are needed to better understand the desired effects of treatment closer to those for target populations for target effects, and in essence with incrementally larger study groups.
Our Medical Group's REACH via not just our 320+ dedicated clinical research staff, but also that of the vast number of board-certified physicians (220+) from seven large scale hospitals, covering the full gamut of therapeutic areas, allows us the ability to obtain quick enrollment numbers for almost any study. Our experience includes the spectrum from local to multi-regional clinical trials and Global Studies, firmly supported by the resources of our five specialized Clinical Research Units strategically located throughout Japan.
A partial list of our Phase 2 and Phase 3 study specialties include:
|Diabetes Mellitus Type II||Anemia||Glaucoma|
|Diabetes Mellitus Type I||Osteoporosis||Hyper Occular Pressure|
|Rheumatoid Arthritis||Endometriosis||Primary Axilla Hyperhidrosis|
|Atopic Dermatitis||Urinary Incontinence||Hypozincemia|
|Insomnia||Hepatitis C||Chronic Myeloid Leukemia|
|Alopecia||Renal Impairment||Acne Vulgaris|
|Gout||Osteoarthritis||Benign Prostatic Hyperplasia|
|Obesity||Hypertension||Mild Cognitive Impairment|
|Irritable Bowel Syndrome||Hepatic Impairment||Parkinson's Disease|
|Narcolepsy||Hyperuricemia||Systemic Lupus Erythematosus|
|Common Cold||Inflammatry Bowel Disease||Hyper Active Bladder Syndrome|
|Alzheimer's Disease||Asymptomatic at Risk for Alzheimer's Dementia|